If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> + REPRODUCTIVE HEALTH<br /> The IVF Shopping List: To<br /> Tick or Not to Tick<br /> + HEPATOLOGY<br /> Cholestasis in the Baby<br /> September 2019 Vol 4.3 ISSN: 2397-6764 and Infant<br /> + RESPIRATORY<br /> Exercise and Rhinitis in Athletes<br /> + EDITOR'S PICK<br /> Systemic Sclerosis: The Role of<br /> YAP/TAZ in Disease Pathogenesis<br /> europeanmedical-journal.com<br /> Use your<br /> smartphone to<br /> vote in polls<br /> and interact<br /> with the<br /> faculty!<br /> Monday 30 September<br /> 17:30–19:00<br /> Room N101-102, IFEMA Feria de Madrid, Spain<br /> Be immersed<br /> in a video<br /> 3D glasses will<br /> be provided!<br /> Optimizing clinical outcomes in asthma<br /> and COPD: focus on inhaler satisfaction<br /> and patient adherence<br /> Selection of the right in<a title="EMJ 4.3 2019 page 1" href="http://viewer.zmags.com/publication/f42cf9bd?page=1"> + REPRODUCTIVE HEALTH The IVF Shopping List: To T</a> <a title="EMJ 4.3 2019 page 2" href="http://viewer.zmags.com/publication/f42cf9bd?page=2"> Use your smartphone to vote in polls and</a> <a title="EMJ 4.3 2019 page 3" href="http://viewer.zmags.com/publication/f42cf9bd?page=3"> EMJ 4.3 Chief Executive Officer Spencer Gore Seni</a> <a title="EMJ 4.3 2019 page 4" href="http://viewer.zmags.com/publication/f42cf9bd?page=4"> Contents + EDITORIAL BOARD </a> <a title="EMJ 4.3 2019 page 5" href="http://viewer.zmags.com/publication/f42cf9bd?page=5"> “In the following pages, we present a ran</a> <a title="EMJ 4.3 2019 page 6" href="http://viewer.zmags.com/publication/f42cf9bd?page=6"> Editorial Board Editor-in-Chief Prof Markus Peck-</a> <a title="EMJ 4.3 2019 page 7" href="http://viewer.zmags.com/publication/f42cf9bd?page=7"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ 4.3 2019 page 8" href="http://viewer.zmags.com/publication/f42cf9bd?page=8"> IN YOUR PATIENTS WITH SEVERE UNCONTROLLED ASTHMA </a> <a title="EMJ 4.3 2019 page 9" href="http://viewer.zmags.com/publication/f42cf9bd?page=9"> Welcome Valued readers, I proudly welcome you to </a> <a title="EMJ 4.3 2019 page 10" href="http://viewer.zmags.com/publication/f42cf9bd?page=10"> THE ART OF RESPIRATORY DIAGNOSTICSSchiller Group </a> <a title="EMJ 4.3 2019 page 11" href="http://viewer.zmags.com/publication/f42cf9bd?page=11"> Foreword Dear colleagues, It is with great pleasu</a> <a title="EMJ 4.3 2019 page 12" href="http://viewer.zmags.com/publication/f42cf9bd?page=12"> PSA doubling time of ≤10 months in nmCRPC despite</a> <a title="EMJ 4.3 2019 page 13" href="http://viewer.zmags.com/publication/f42cf9bd?page=13"> PUSH BACK ON PROGRESSION INTRODUCING ERLEADA® IN </a> <a title="EMJ 4.3 2019 page 14" href="http://viewer.zmags.com/publication/f42cf9bd?page=14"> The IVF Shopping List: To Tick or Not to Tick </a> <a title="EMJ 4.3 2019 page 15" href="http://viewer.zmags.com/publication/f42cf9bd?page=15"> the Provoost model is a consensus-based model. A </a> <a title="EMJ 4.3 2019 page 16" href="http://viewer.zmags.com/publication/f42cf9bd?page=16"> This paper describes the application of the</a> <a title="EMJ 4.3 2019 page 17" href="http://viewer.zmags.com/publication/f42cf9bd?page=17"> investigate miscarriage, a significant reduction i</a> <a title="EMJ 4.3 2019 page 18" href="http://viewer.zmags.com/publication/f42cf9bd?page=18"> EMBRYO GLUE The use of hyaluronan-rich (HA) suppl</a> <a title="EMJ 4.3 2019 page 19" href="http://viewer.zmags.com/publication/f42cf9bd?page=19"> The inconclusive and sometimes contradictory resu</a> <a title="EMJ 4.3 2019 page 20" href="http://viewer.zmags.com/publication/f42cf9bd?page=20"> grades of sensitivity are different, generat</a> <a title="EMJ 4.3 2019 page 21" href="http://viewer.zmags.com/publication/f42cf9bd?page=21"> References 1. Harper J et al. Adjuncts in th</a> <a title="EMJ 4.3 2019 page 22" href="http://viewer.zmags.com/publication/f42cf9bd?page=22"> Variability of Biologics and its Impact </a> <a title="EMJ 4.3 2019 page 23" href="http://viewer.zmags.com/publication/f42cf9bd?page=23"> factors that must be considered during clinical d</a> <a title="EMJ 4.3 2019 page 24" href="http://viewer.zmags.com/publication/f42cf9bd?page=24"> protected sales could be replaced by more a</a> <a title="EMJ 4.3 2019 page 25" href="http://viewer.zmags.com/publication/f42cf9bd?page=25"> Clinical trials PK/PD Preclinical Biologi</a> <a title="EMJ 4.3 2019 page 26" href="http://viewer.zmags.com/publication/f42cf9bd?page=26"> across the key effector functionalities associate</a> <a title="EMJ 4.3 2019 page 27" href="http://viewer.zmags.com/publication/f42cf9bd?page=27"> less suitable in certain situations, including in</a> <a title="EMJ 4.3 2019 page 28" href="http://viewer.zmags.com/publication/f42cf9bd?page=28"> Response, % (90% Cl) ORR by independent central r</a> <a title="EMJ 4.3 2019 page 29" href="http://viewer.zmags.com/publication/f42cf9bd?page=29"> increases in biosimilar uptake are likely to lead</a> <a title="EMJ 4.3 2019 page 30" href="http://viewer.zmags.com/publication/f42cf9bd?page=30"> based-EU perspective. 2017. Available at: https:/</a> <a title="EMJ 4.3 2019 page 31" href="http://viewer.zmags.com/publication/f42cf9bd?page=31"> Moderate Psoriatic Arthritis and Perspectives fro</a> <a title="EMJ 4.3 2019 page 32" href="http://viewer.zmags.com/publication/f42cf9bd?page=32"> Introduction: Moderate Psoriatic Arthritis - Wha</a> <a title="EMJ 4.3 2019 page 33" href="http://viewer.zmags.com/publication/f42cf9bd?page=33"> Blood/lymphoid tissue Th1 TH17 </a> <a title="EMJ 4.3 2019 page 34" href="http://viewer.zmags.com/publication/f42cf9bd?page=34"> patients with PsA have at least two conditions ot</a> <a title="EMJ 4.3 2019 page 35" href="http://viewer.zmags.com/publication/f42cf9bd?page=35"> Psoriatic Disease Activity Index tools were able </a> <a title="EMJ 4.3 2019 page 36" href="http://viewer.zmags.com/publication/f42cf9bd?page=36"> Learnings from Phosphodiesterase-</a> <a title="EMJ 4.3 2019 page 37" href="http://viewer.zmags.com/publication/f42cf9bd?page=37"> Summary Patients with moderate PsA represent a re</a> <a title="EMJ 4.3 2019 page 38" href="http://viewer.zmags.com/publication/f42cf9bd?page=38"> 6. Merola JF et al. Distinguishing rhe</a> <a title="EMJ 4.3 2019 page 39" href="http://viewer.zmags.com/publication/f42cf9bd?page=39"> 46. Coates LC et al. AB0741 Achievement </a> <a title="EMJ 4.3 2019 page 40" href="http://viewer.zmags.com/publication/f42cf9bd?page=40"> Antineutrophil Cytoplasmic Antibody-Associated</a> <a title="EMJ 4.3 2019 page 41" href="http://viewer.zmags.com/publication/f42cf9bd?page=41"> CURRENT CHALLENGES The antineutrophil cytoplasmic</a> <a title="EMJ 4.3 2019 page 42" href="http://viewer.zmags.com/publication/f42cf9bd?page=42"> ophthalmologist. “It is quite a challenge t</a> <a title="EMJ 4.3 2019 page 43" href="http://viewer.zmags.com/publication/f42cf9bd?page=43"> consequence of delayed disease control. Further t</a> <a title="EMJ 4.3 2019 page 44" href="http://viewer.zmags.com/publication/f42cf9bd?page=44"> Prof de Groot. Prof Bruchfeld agreed, “In general</a> <a title="EMJ 4.3 2019 page 45" href="http://viewer.zmags.com/publication/f42cf9bd?page=45"> LOOKING AHEAD Considering the future of treatment</a> <a title="EMJ 4.3 2019 page 46" href="http://viewer.zmags.com/publication/f42cf9bd?page=46"> Prof Kirsten de Groot Medical Clinic III (Interna</a> <a title="EMJ 4.3 2019 page 47" href="http://viewer.zmags.com/publication/f42cf9bd?page=47"> Systemic Sclerosis: The Role of YAP/TAZ in </a> <a title="EMJ 4.3 2019 page 48" href="http://viewer.zmags.com/publication/f42cf9bd?page=48"> INTRODUCTION Systemic sclerosis (SSc) is </a> <a title="EMJ 4.3 2019 page 49" href="http://viewer.zmags.com/publication/f42cf9bd?page=49"> B-Cell </a> <a title="EMJ 4.3 2019 page 50" href="http://viewer.zmags.com/publication/f42cf9bd?page=50"> Epithelial/endothelial cell Tense actin belt Adh</a> <a title="EMJ 4.3 2019 page 51" href="http://viewer.zmags.com/publication/f42cf9bd?page=51"> YAP/TAZ. It may participate in both promoting and</a> <a title="EMJ 4.3 2019 page 52" href="http://viewer.zmags.com/publication/f42cf9bd?page=52"> pneumonitis (n=15) versus non-nuclear expression </a> <a title="EMJ 4.3 2019 page 53" href="http://viewer.zmags.com/publication/f42cf9bd?page=53"> TEAD 4 directly targets peroxisome proliferator- </a> <a title="EMJ 4.3 2019 page 54" href="http://viewer.zmags.com/publication/f42cf9bd?page=54"> to have low levels of caveolin-1 leading t</a> <a title="EMJ 4.3 2019 page 55" href="http://viewer.zmags.com/publication/f42cf9bd?page=55"> References 1. Zhao B et al. The Hippo–YAP </a> <a title="EMJ 4.3 2019 page 56" href="http://viewer.zmags.com/publication/f42cf9bd?page=56"> 44. Yeo MK et al. Expression pattern </a> <a title="EMJ 4.3 2019 page 57" href="http://viewer.zmags.com/publication/f42cf9bd?page=57"> Noninvasive Imaging Modalities in Nonalcoholic </a> <a title="EMJ 4.3 2019 page 58" href="http://viewer.zmags.com/publication/f42cf9bd?page=58"> a key role in ruling out focal liver lesions and </a> <a title="EMJ 4.3 2019 page 59" href="http://viewer.zmags.com/publication/f42cf9bd?page=59"> Magnetic Resonance Spectroscopy MR spectroscopy (</a> <a title="EMJ 4.3 2019 page 60" href="http://viewer.zmags.com/publication/f42cf9bd?page=60"> are limited; thus, further studies are needed to </a> <a title="EMJ 4.3 2019 page 61" href="http://viewer.zmags.com/publication/f42cf9bd?page=61"> disease. Ann Hepatol. 2008;7(3):212- 26. 20.</a> <a title="EMJ 4.3 2019 page 62" href="http://viewer.zmags.com/publication/f42cf9bd?page=62"> 51. Ferraioli G et al. WFUMB guidelines </a> <a title="EMJ 4.3 2019 page 63" href="http://viewer.zmags.com/publication/f42cf9bd?page=63"> Scalp Sarcoidosis with Systemic Involvement: A </a> <a title="EMJ 4.3 2019 page 64" href="http://viewer.zmags.com/publication/f42cf9bd?page=64"> of several irregularly round and confluent patches</a> <a title="EMJ 4.3 2019 page 65" href="http://viewer.zmags.com/publication/f42cf9bd?page=65"> A B Figure 2: Trichoscopy of the </a> <a title="EMJ 4.3 2019 page 66" href="http://viewer.zmags.com/publication/f42cf9bd?page=66"> DISCUSSION Sarcoidosis is an idiopathic chron</a> <a title="EMJ 4.3 2019 page 67" href="http://viewer.zmags.com/publication/f42cf9bd?page=67"> but with a poor response. High potency topical st</a> <a title="EMJ 4.3 2019 page 68" href="http://viewer.zmags.com/publication/f42cf9bd?page=68"> A Versatile, Low-Cost, Three-Dimensional-Printed </a> <a title="EMJ 4.3 2019 page 69" href="http://viewer.zmags.com/publication/f42cf9bd?page=69"> When fluid collections are smaller, care</a> <a title="EMJ 4.3 2019 page 70" href="http://viewer.zmags.com/publication/f42cf9bd?page=70"> the suprapatellar effusion was created using</a> <a title="EMJ 4.3 2019 page 71" href="http://viewer.zmags.com/publication/f42cf9bd?page=71"> Figure 2: A) Suprapatellar short-axis view of kne</a> <a title="EMJ 4.3 2019 page 72" href="http://viewer.zmags.com/publication/f42cf9bd?page=72"> was created by the food storage container to allo</a> <a title="EMJ 4.3 2019 page 73" href="http://viewer.zmags.com/publication/f42cf9bd?page=73"> Cholestasis in the Baby and Infant Authors: </a> <a title="EMJ 4.3 2019 page 74" href="http://viewer.zmags.com/publication/f42cf9bd?page=74"> AETIOLOGY In children and neonates, cholestas</a> <a title="EMJ 4.3 2019 page 75" href="http://viewer.zmags.com/publication/f42cf9bd?page=75"> Table 1 continued. Idiopathic Idiopathic neo</a> <a title="EMJ 4.3 2019 page 76" href="http://viewer.zmags.com/publication/f42cf9bd?page=76"> The diseases that are important causes of c</a> <a title="EMJ 4.3 2019 page 77" href="http://viewer.zmags.com/publication/f42cf9bd?page=77"> Bile Acid Synthesis Disorders/Inborn Errors of Bi</a> <a title="EMJ 4.3 2019 page 78" href="http://viewer.zmags.com/publication/f42cf9bd?page=78"> of this gene is limited to the liver; therefore, </a> <a title="EMJ 4.3 2019 page 79" href="http://viewer.zmags.com/publication/f42cf9bd?page=79"> Some newborns with cholestasis can present with </a> <a title="EMJ 4.3 2019 page 80" href="http://viewer.zmags.com/publication/f42cf9bd?page=80"> therapeutic irrigation of inspissated bile from t</a> <a title="EMJ 4.3 2019 page 81" href="http://viewer.zmags.com/publication/f42cf9bd?page=81"> Rifampicin acts by upregulating detoxification enz</a> <a title="EMJ 4.3 2019 page 82" href="http://viewer.zmags.com/publication/f42cf9bd?page=82"> (eds.), Liver diseases in children </a> <a title="EMJ 4.3 2019 page 83" href="http://viewer.zmags.com/publication/f42cf9bd?page=83"> Acquired Sperm DNA Modifications: Causes, Con</a> <a title="EMJ 4.3 2019 page 84" href="http://viewer.zmags.com/publication/f42cf9bd?page=84"> is also the source of two developmentally i</a> <a title="EMJ 4.3 2019 page 85" href="http://viewer.zmags.com/publication/f42cf9bd?page=85"> free ends and therefore generates the chiasma.10 </a> <a title="EMJ 4.3 2019 page 86" href="http://viewer.zmags.com/publication/f42cf9bd?page=86"> Even though small amounts of ROS are normally pro</a> <a title="EMJ 4.3 2019 page 87" href="http://viewer.zmags.com/publication/f42cf9bd?page=87"> fact, Sertoli cells not only participate in the g</a> <a title="EMJ 4.3 2019 page 88" href="http://viewer.zmags.com/publication/f42cf9bd?page=88"> nucleolar precursor bodies (NPB) in the male and </a> <a title="EMJ 4.3 2019 page 89" href="http://viewer.zmags.com/publication/f42cf9bd?page=89"> Excessive ROS can be of both endogenous (sp</a> <a title="EMJ 4.3 2019 page 90" href="http://viewer.zmags.com/publication/f42cf9bd?page=90"> Figure 2: Sperm intranuclear vacuoles observed in</a> <a title="EMJ 4.3 2019 page 91" href="http://viewer.zmags.com/publication/f42cf9bd?page=91"> References 1. Rathke C et al. Chromatin dyna</a> <a title="EMJ 4.3 2019 page 92" href="http://viewer.zmags.com/publication/f42cf9bd?page=92"> human spermatozoa. J Reprod Fert. 60. 1987</a> <a title="EMJ 4.3 2019 page 93" href="http://viewer.zmags.com/publication/f42cf9bd?page=93"> 88. Tesarik J, Kopecny V. Nucleic acid s</a> <a title="EMJ 4.3 2019 page 94" href="http://viewer.zmags.com/publication/f42cf9bd?page=94"> We want you to write for the EMJ </a> <a title="EMJ 4.3 2019 page 95" href="http://viewer.zmags.com/publication/f42cf9bd?page=95"> INTRODUCTION Food allergy (FA) is a potentially l</a> <a title="EMJ 4.3 2019 page 96" href="http://viewer.zmags.com/publication/f42cf9bd?page=96"> treatment. Desensitisation could achieve disease </a> <a title="EMJ 4.3 2019 page 97" href="http://viewer.zmags.com/publication/f42cf9bd?page=97"> to the available experimental data, a prope</a> <a title="EMJ 4.3 2019 page 98" href="http://viewer.zmags.com/publication/f42cf9bd?page=98"> Over 50.0% of children with HE allergy develop na</a> <a title="EMJ 4.3 2019 page 99" href="http://viewer.zmags.com/publication/f42cf9bd?page=99"> with negative sIgE outgrew their allergy.32,33 Fo</a> <a title="EMJ 4.3 2019 page 100" href="http://viewer.zmags.com/publication/f42cf9bd?page=100"> References 1. Pajno GB et al. Allergen </a> <a title="EMJ 4.3 2019 page 101" href="http://viewer.zmags.com/publication/f42cf9bd?page=101"> Primary Sclerosing Cholangitis: A Cl</a> <a title="EMJ 4.3 2019 page 102" href="http://viewer.zmags.com/publication/f42cf9bd?page=102"> AND PATHOGENESIS EPIDEMIOLOGY, GENETICS, PSC is </a> <a title="EMJ 4.3 2019 page 103" href="http://viewer.zmags.com/publication/f42cf9bd?page=103"> seen in patients with PSC. Albumin is normal in e</a> <a title="EMJ 4.3 2019 page 104" href="http://viewer.zmags.com/publication/f42cf9bd?page=104"> RHD LHD CD CHD RAH CBD MPD MF 1.76 GB Figur</a> <a title="EMJ 4.3 2019 page 105" href="http://viewer.zmags.com/publication/f42cf9bd?page=105"> Table 1: Causes of secondary sclerosing cholangit</a> <a title="EMJ 4.3 2019 page 106" href="http://viewer.zmags.com/publication/f42cf9bd?page=106"> The addition of fluorescent in situ hybridisation </a> <a title="EMJ 4.3 2019 page 107" href="http://viewer.zmags.com/publication/f42cf9bd?page=107"> the other hand do not endorse use of UDCA for pre</a> <a title="EMJ 4.3 2019 page 108" href="http://viewer.zmags.com/publication/f42cf9bd?page=108"> altered anatomy that prevents successful ERCP, su</a> <a title="EMJ 4.3 2019 page 109" href="http://viewer.zmags.com/publication/f42cf9bd?page=109"> References 1. Aoki CA et al. The immunobiolo</a> <a title="EMJ 4.3 2019 page 110" href="http://viewer.zmags.com/publication/f42cf9bd?page=110"> cholangitis. Am J Gastroenterol. 2011;106(9):1638</a> <a title="EMJ 4.3 2019 page 111" href="http://viewer.zmags.com/publication/f42cf9bd?page=111"> Polymyalgia Rheumatica and Seronegative El</a> <a title="EMJ 4.3 2019 page 112" href="http://viewer.zmags.com/publication/f42cf9bd?page=112"> sedimentation rate [ESR] and C-reactive p</a> <a title="EMJ 4.3 2019 page 113" href="http://viewer.zmags.com/publication/f42cf9bd?page=113"> having RA.34 To detect early RA, on the other han</a> <a title="EMJ 4.3 2019 page 114" href="http://viewer.zmags.com/publication/f42cf9bd?page=114"> AND YOUNG-ONSET RHEUMATOID ARTHRITIS DIFFERENCES</a> <a title="EMJ 4.3 2019 page 115" href="http://viewer.zmags.com/publication/f42cf9bd?page=115"> pathognomonic findings.64,65 As highlighted by the</a> <a title="EMJ 4.3 2019 page 116" href="http://viewer.zmags.com/publication/f42cf9bd?page=116"> In some patients, small doses of GC are necessary</a> <a title="EMJ 4.3 2019 page 117" href="http://viewer.zmags.com/publication/f42cf9bd?page=117"> patients with SEORA, short term treatment with </a> <a title="EMJ 4.3 2019 page 118" href="http://viewer.zmags.com/publication/f42cf9bd?page=118"> recommendations for the management of rheumatoid </a> <a title="EMJ 4.3 2019 page 119" href="http://viewer.zmags.com/publication/f42cf9bd?page=119"> 2015 European League Against Rheumatism/American </a> <a title="EMJ 4.3 2019 page 120" href="http://viewer.zmags.com/publication/f42cf9bd?page=120"> Exercise and Rhinitis in Athletes Authors: </a> <a title="EMJ 4.3 2019 page 121" href="http://viewer.zmags.com/publication/f42cf9bd?page=121"> with the distinctive, and often severe, symptom b</a> <a title="EMJ 4.3 2019 page 122" href="http://viewer.zmags.com/publication/f42cf9bd?page=122"> Exercise-induced changes in nasal secretions </a> <a title="EMJ 4.3 2019 page 123" href="http://viewer.zmags.com/publication/f42cf9bd?page=123"> Bougault et al.9 who showed significantl</a> <a title="EMJ 4.3 2019 page 124" href="http://viewer.zmags.com/publication/f42cf9bd?page=124"> corticosteroids, and immunotherapy. Nowadays, S</a> <a title="EMJ 4.3 2019 page 125" href="http://viewer.zmags.com/publication/f42cf9bd?page=125"> medications that may fall foul of anti-doping reg</a> <a title="EMJ 4.3 2019 page 126" href="http://viewer.zmags.com/publication/f42cf9bd?page=126"> 25. Erkul E et al. Effects of indoor swi</a> <a title="EMJ 4.3 2019 page 127" href="http://viewer.zmags.com/publication/f42cf9bd?page=127"> What's New Adolescents’ Kidney and Liver Functio</a> <a title="EMJ 4.3 2019 page 128" href="http://viewer.zmags.com/publication/f42cf9bd?page=128"> What's New A Novel Toolkit for the</a> <a title="EMJ 4.3 2019 page 129" href="http://viewer.zmags.com/publication/f42cf9bd?page=129"> "Gold-silica nanoshells infusion allows for a fo</a> <a title="EMJ 4.3 2019 page 130" href="http://viewer.zmags.com/publication/f42cf9bd?page=130"> Never miss an update again. </a>